611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

NurseWise 24-Hour Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

NurseWise 24-Hr Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Medical Disorders
Resources
Basic InformationLookupsLatest News
Health Tip: Relieve Ear Pressure While FlyingBlack Children Missing Out on Eczema TreatmentNew Framework Guides Tx Decisions for Atopic DermatitisHealth Tip: Recognizing SepsisAround the World, Too Little Relief for PainNearly 4 in 10 U.S. Adults Now ObeseFDA Panel Supports Gene Therapy for Kids With Rare Eye Disease30-Day Mortality Lower With Female SurgeonsDirect Primary Care May Fill Niche for Uninsured3 Factors That Could Raise Your Risk of Bloodstream InfectionStroke Risk Factors Are RisingTwo Ebola Vaccines Spur Lasting Immune ResponseHormone Therapy May Be OK for Women With MigrainesMigraine MattersMedial Temporal Lobe Surgery Linked to Prevalence of TinnitusHigher Levels of Fungus ID'd in Patients With Crohn'sWhere There's Type 1 Diabetes, Celiac Disease May FollowAntibiotic Use Not Linked to Islet, Celiac Disease AutoimmunitySome U.S. Olympians Got West Nile in Brazil, But Not ZikaPenicillin Misconceptions May Raise Post-Op Infection RiskHate UTIs? One Simple Step Can Cut the RiskIDSA: Retail Meat May Be a Transmission Source for UTIsLonger Anesthesia Duration Tied to More Surgical ComplicationsFirst Test to Detect Zika in Blood Donations ApprovedHealth Tip: Learn Symptoms of Childhood SinusitisLimiting 'Cold Time' Could Make More Organs Available for TransplantHealth Literacy Linked to Length of Stay After Abdominal SurgeryZika Vaccine Works in Early Human TrialHealth Tip: Understanding Loud Noise and Hearing LossAllergy Relief Do's and Don'tsPatient Factors Differ for Surgical, All-Cause ReadmissionComing Soon: A Faster Test for Antibiotics Against UTIs?Antibody Injections in Pregnancy Might Shield Fetus From ZikaHealth Tip: Giving BloodMore U.S. Measles Cases From No Vaccine vs. Imported DiseaseHigh Epsom Salt Intake Can Lead to Severe Liver InjuryTattoo Pigment Hypersensitivity Can Mimic LymphomaObesity Linked to 13 Types of CancerBlood Thinners Can Come With Dangerous Side EffectsMeasles Making a Comeback in the United StatesAfter Deepwater Oil Cleanup in Gulf, Ill Effects PersistState Laws Can Promote Hepatitis C Virus ScreeningHow Much Alcohol Is Really OK?Girls' Sports-Related Concussions May Last Twice As LongSingle Mutation Made Zika Virus More VirulentVi-Tetanus Toxoid Conjugate Vaccine Can Prevent TyphoidDialysis Patients Often End Up Back in the HospitalRespiratory Disease Death Rates Have SoaredGenetic Tweaks in Mosquitoes Might Curb Malaria TransmissionImmunochromatography Testing Differentiates Dengue, Zika
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

Drug Beats Steroids for Controlling Blood Vessel Inflammation in Study

HealthDay News
by -- Robert Preidt
Updated: Jul 26th 2017

new article illustration

WEDNESDAY, July 26, 2017 (HealthDay News) -- The drug tocilizumab performs better than steroids in treating the most common form of blood vessel inflammation known as giant cell arteritis, a new study has shown.

The phase 3 clinical trial of 251 patients confirmed that tocilizumab (Actemra) reduced symptoms and also the need for high-dose steroid treatment for the condition. Phase 3 clinical trials represent the last phase before approval for general use. They compare the safety and effectiveness of the new treatment against the current standard treatment.

The trial results led to the U.S. Food and Drug Administration's recent approval of tocilizumab to treat giant cell arteritis. It's the first new treatment for arterial inflammation in more than 50 years.

"Giant cell arteritis affects around 250,000 individuals in the U.S. alone, targeting people over the age of 50, and is three times more likely in women," said study lead author Dr. John Stone, a rheumatologist at Massachusetts General Hospital.

"This trial is the first to demonstrate beyond any doubt that an alternative to chronic, unending steroid treatment exists," Stone said in a hospital news release.

"One of the most surprising findings was just how poorly the traditional, steroid-only regimens worked. These results are likely to have an immediate, sustained impact on the lives of hundreds of thousands of patients across the world," he said.

Giant cell arteritis primarily affects arteries in the head, neck and eyes, as well as the aorta and its primary branches. It causes blindness in up to 20 percent of patients. They are also at increased risk for stroke and aortic aneurysms.

Symptoms of giant cell arteritis include headache, pain in the scalp or other areas, and changes in vision, which can be sudden.

Until now, steroids have been the only effective treatment. But most patients require high doses of steroids, which can cause serious side effects such as weight gain, body fat redistribution, osteoporosis, mood changes, high blood pressure, glucose intolerance and increased risk of infection, the researchers said.

Actemra injections are already used to treat rheumatoid arthritis.

The study results were published July 26 in the New England Journal of Medicine.

More information

The American College of Rheumatology has more on giant cell arteritis.